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Abstract. Mefenamic acid [2-(2, 3-dimethylphenyl) amino benzoic acid] is an active 
pharmaceutical compound that exist in different polymorphic form and shape. In this work the 
effect of solvents on polymorphism and shape of mefenamic acid crystals were examined. The 
solvents used were ethanol, isopropanol, ethyl acetate, dimethyl acetamide, dimethyl formamide, 
and acetone. Natural cooling was employed during the crystallisation process. The crystals 
produced were dried and analysed using optical microscopy, differential scanning calorimetry, 
thermal gravimetric analysis, x-ray powder diffraction (XRPD) and fourier transform infrared 
spectroscopy (FTIR). The analysis confirmed that the crystals obtained using ethyl acetate, ethanol, 
isopropanol, and acetone are pure Form I with a needle-like flat shape. Meanwhile, the 
crystallisation using DMF produced polymorphic Form II in cubic shape.   
1 Introduction  
Solvent demonstrate an important role in the 
crystallisation process as it can contribute to the 
polymorphic selectivity of targeted pharmaceutical 
compound [1, 2]. This is because, at the molecular level, 
the solvent can selectively adsorb onto the crystals faces 
or interact with the solute clusters. The solvent-solute 
interactions, i.e. hydrogen bonding have been proven to 
affect the birth of different polymorphic forms [3]. A 
solvent molecule that has a stronger ability to donate or 
accept hydrogen bonding than the solute molecule may 
establish hydrogen bonding network with the solute 
molecule, resulting in selective nucleation [4]. For 
example, crystallisation of sulfathiazole using water 
produces polymorphic Form II and III. The polymorphic 
Forms I and IV are obtained from acetone, while n-
propanol gives only Form I [5].  
The types of solvent used during the crystallisation 
process also influence the shape of the crystals. Garti and 
co-worker reported that the crystallisation of cholesterol 
using ethanol and acetonitrile produced needles and 
plate-like crystal, respectively [6]. Ibuprofen crystals that 
crystallized from polar solvents, such as ethanol and 
acetone and non-polar solvents, such as diethyl ether and 
hexane, produced needle-like crystals. In contrast, 
crystallisation of ibuprofen using dichloromethane and 
acetonitrile produced cubic and spherical agglomerates, 
respectively [7]. The external structure has profound 
effect on orientation of particle, and thus may cause 
differences in packing, powder flow, compaction, 
syringability, stability of suspension, and dissolution 
characteristics [2].   
Mefenamic acid (2-[(2,3-dimethylphenyl) amino] 
benzoic acid, C15H15NO2) is a widely used nonsteroidal 
anti-inflamatory and analgesic agent for treatment of 
pain cause by menstrual disorders was reported to exist 
in three polymorphic forms: Form I, Form II and Form 
III [8-10]. The polymorphs are enantiotropically related 
and show different physicochemical properties which in 
turn affect the process acceptability, bioavailability and 
performance of the final product. The habit of 
mefenamic acid crystals can be either plate or needle 
shaped depending on the crystallisation conditions. 
Numerous research works on mefenamic acid crystals 
have resulted in the availability of different methods 
using various solvents for producing a particular 
polymorph [8, 9]. However, most of the literatures are 
difficult to follow as they do not state the initial solute 
concentration.  
This paper presents the work on investigation of 
various types of solvents, which classified into polar 
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protic (ethanol and isopropanol) and dipolar aprotic 
(ethyl acetate, dimethyl acetamide, dimethyl formamide, 
and acetone) on polymorphism and habit of mefenamic 
acid crystals. Apolar aprotic solvents such as hexane, 
cyclohexane and heptane were not considered as 
crystallisation solvent due to its poor solubility 
characteristics [11]. In order to understand and 
differentiate the characteristics of crystals produced, 
comprehensive characterizations were performed using 
various analytical techniques, i.e. thermal, microscopy, 
infrared spectroscopy and x-ray diffraction. The 
experimental results were compared with those of 
previous workers whenever possible.  
2 Methodology  
2.1. Material 
Mefenamic acid powder with purity of 98 wt% was 
obtained from Baoji Tianxin Pharmaceutical Co. Ltd., 
China. The solvents used namely ethanol, ethyl acetate 
(EA), isopropanol (IPA), dimethyl acetamide (DMA), 
dimethyl formamide (DMF) and acetone were analytical 
grade with >99 wt % purity and supplied by Fisher 
Scientific.   
2.2 Crystallisation method  
Saturated solution of mefenamic acid was prepared by 
dissolving known amount of mefenamic acid in 50 mL 
of solvents studied. The amount of mefenamic acid used 
as tabulated in Table 1 is based on solubility data 
reported in our previous work [11]. The solution 
prepared was heated on a hot plate at 60°C except for 
DMF and acetone, which was at 50°C until dissolution. 
Then, the solution was allow to cool to room temperature 
through natural cooling. The crystals produced were 
filtered and dried in an oven at 60°C. The crystals were 
periodically dried and weighed until constant weight was 
achieved. The dried crystals were stored in a screw cap 
glass vials for further characterization works.  
Table 1. Amount of mefenamic acid used in different solvents. 
Method Solvent Amount of Mefenamic Acid 
(g) 
1 
Ethyl 
actetate 
1.59  
2 Ethanol 1.14  
3 Isopropanol 1.23  
4 Dimethyl 
formamide 
8.60  
5 Dimethyl 
acetamide 
33.87  
6 Acetone 2.70  
2.3 Characterisation methods  
The images of the crystals were captured using Leica 
microscope DM750 with a total magnification of 
200x4x/0.10 and processed using Leica Application 
Suite Software version 3.6. The FTIR spectra of crystals 
from 500 to 4000 cm-1 were obtained using Perkin 
Elmer’s ATR-FTIR Spectrometer (Frontier). The spectra 
were analyzed using OMNIC software with an average 
scan of 16 [12].  
 The melting properties analysis was performed using 
a Mettler Toledo DSC-1 from temperature of 25 to 
300oC at a heating rate of 10 ᵒC/min under constant 
purging of nitrogen [9]. About 2-10 mg of crystals was 
weighed into a 40 μL standards aluminum pan with lid 
and sealed hermetically prior to analysis. An empty 
aluminum pan was used as a reference in all the runs.  
The results were analyzed using Mettler Toledo Stare 
SW 9.10. The TA Instruments (Q500/50) was also used 
to study the changes of weight derivatives with 
temperature. Sample with a weight range of 4-6 mg was 
placed on a platinum pan and heated from 25 to 300°C at 
a constant heating rate of 10 °C / min.  
 The x-ray powder diffraction patterns were recorded 
using Shimadzu XRD 6000 equipped vertical x-ray 
goniometer and Cu Kα radiation with angle 
reproducibility of ±0.001o (2θ). Prior to analysis, the 
crystals were initially placed into an aluminum holder 
and gently grinded, pressed and flatten softly using 
spatula and glass plate. The measurement conditions 
used were: 40 kV of voltage; 30 mA of current; 5-50ᵒ 
(2θ) of scan range; 0.05o of step size and 3ᵒ/min of scan 
mode in a continuous mode [9].   
3 Results and Discussion 
3.3.1 Shape of crystals 
Shape or habit of crystals of may influence the bulk 
density, flowability and mechanical strength of the 
pharmaceutical compound [13]. Fig. 1 shows the shapes 
of crystals produced using different solvents. As seen in 
Fig. 1 (a), (b), (c) and (f), mefenamic acid which 
crystallised using EA, ethanol, IPA, and acetone, 
respectively are elongated needle-like flat shaped 
crystals and consistent with those reported in the 
literature [8, 14, 15]. Fig. 1 (d) shows that the crystals 
crystallised from DMF are cubic-shaped. Meanwhile, the 
crystallisation using DMA produced a plate-like-shaped 
crystals (Fig. 1 (e)). A comparison, however, cannot be 
made for crystals obtained using DMA as it is yet to be 
reported in the literature.  
The difference in crystal shapes produced in this 
work are probably due to the variation of solvents’ 
polarity which results in different solute-solvent 
interactions at the crystal’s facets. The crystallographic 
structure of mefenamic acid obtained from Lee and co-
workers shows the presence of –OH, -C=O and –C6H5 
which were exposed on the crystal facet (0 0 1) [16]. The 
–OH and -C=O have significant hydrogen bonding 
ability and thus, may permit strong hydrogen bonding 
interactions between facet (0 0 1) and solvents with high 
polarity. Based on the polarity index, DMF is expected 
to form stronger interactions with the facet (0 0 1) 
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Fig. 2. Partial infrared spectra of of mefenamic acid samples: 
a) as received, and after crystallised using (b) ethyl acetate, 
(c) ethanol, (d) IPA, (e) DMF, (f) DMA, and (g) acetone. 
 
followed by DMA, ethanol, propanone IPA, and EA. 
The strong hydrogen bonding interactions between the 
facet and solvent will consequently reduce the interfacial 
tensions and enhance the growth of the crystal facet. The 
relative contribution of the facet, however, decreases 
with the increase of solvent’s polarity [15]. This 
phenomenon explained the reduction of crystal length 
produced using DMF and DMA solvents as shown in 
Fig. 1 (d) and (e), respectively.   
 
   
(a) (b) 
 
(c) 
   
(d) (e) (f) 
Fig. 1. Optical microscopy images of crystals obtained from crystallisation using different solvents: (a) ethyl acetate; (b) ethanol; (c) 
IPA; (d) DMF; (e) DMA; and (f) acetone.  
3.3.2 Infrared spectroscopy 
Fig. 2 shows partial infrared spectra for mefenamic acid 
crystals as received from the supplier and after 
crystallisation using different solvents. As shown by the 
dashed vertical line in Fig. 2, the crystals obtained after 
crystallised using EA, ethanol, IPA, DMA, and acetone 
have N-H stretching band at approximately 3313 cm-1, 
which corresponds to Form I of mefenamic acid. The 
crystals obtained using DMF as solvents show N-H 
stretching at 3347 cm-1, which correspond to Form II. 
The higher wavelength observed for the N-H stretching 
of mefenamic acid Form II suggests a weaker hydrogen 
interaction between carboxylic groups in comparison 
with mefenamic acid Form I [14]. Previous works also 
highlighted that the N-H stretching band that occurs 
between 3300 and 3350 cm-1 is an important spectrum 
that can be used to distinguish either Form I or Form II 
of mefenamic acid [17, 21].  
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Fig. 2. Partial infrared spectra of of mefenamic acid samples: 
a) as received, and after crystallised using (b) ethyl acetate, 
(c) ethanol, (d) IPA, (e) DMF, (f) DMA, and (g) acetone. 
 
 
 
3.3.3 Thermal behaviour 
The differential scanning calorimetry (DSC) and thermal 
gravimetric (TG) curves of mefenamic acid after 
crystallisation using different solvents are shown in Fig. 
3 (a) until (f). The DSC curve in Fig. 3 (a), (b), (c), (e), 
and (f) have two endothermic peaks.  The onset 
temperature of the first endothermic peak of mefenamic 
acid shown in those figures varied from 168.82 to 
190.16°C. Meanwhile, for the second endothermic peak, 
the values are from 226.75 to 232.08°C. These values 
concur with those values of mefenamic acid Form I 
reported in the literature [9, 12, 14, 17]. The temperature 
of the first and second endothermic peaks represent the 
transition temperature, TT  of Form I to Form II and the 
melting or fusion, Tf  of Form II, respectively. The 
presence of an endothermic peak before the melting 
point shows that the mefenamic acid polymorphs are 
enantiotropic, where it can reversibly transform into one 
another by cooling or heating process [14].  
The DSC curve of mefenamic acid crystallised using 
DMF as shown in Fig. 3 (d) on the other hand, only has 
one endothermic peak with molar enthalpy of fusion of 
38.31±5.51 kJmol-1. This value is comparable with those 
reported by literature, which is 38.243, 38.7 and 40.39 
kJmol-1 [12, 18]. The endothermic peak is associated 
with the molecule decomposition [14]. The DSC curve 
with one endothermic peak is consistent with mefenamic 
acid Form II characteristic [14]. The derivative TG 
curves shown in Fig. 3 (a) until (f) are presented to 
provide correlation between the weight loss and the 
calorimetric profile. The curves show a significant 
derivative weight change between 165 and 245°C, which 
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is approximately at the second endothermic peak of the 
DSC curve. The change in the derivative weight is 
believed due to the decomposition of mefenamic acid 
crystals during the melting process. In addition, no 
significant derivative weight was detected in the region 
of 80 to 100°C, whereas in many cases, it may cause the 
decomposition of the substrate material or volatilisation 
of residual solvents [19]. 
 
 
(a) 
 
(b) 
 
(c)  
(d) 
 
(e)  (f) 
 
Fig. 3. DSC and derivative TGA curves of mefenamic acid crystals obtained by (a) ethyl acetate; (b) ethanol; (c) IPA; (d) DMF; (e) 
DMA; and (f) acetone. 
Derivative 
TG curve 
DSC curve 
DSC curve 
Derivative 
TG curve 
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3.3.4 Phase analysis 
The XRPD pattern of mefenamic acid crystals obtained 
from EA, ethanol, IPA, DMA and acetone in comparison 
with some major reflections in the reference pattern of 
Form I reported literature [8, 20] is shown in Fig. 4 (a), 
(b), (c), (d) and (e), respectively. The pattern concurs 
with the literature. In addition, any significant peaks at 
11.8°, 17.9°, 23.8° and 25.6°, as well as 9-12° (2θ) 
which represent Form II of mefenamic acid were not 
observed. This confirms that pure Form I crystals were 
successfully produced using ethyl acetate, ethanol, IPA, 
DMA and acetone.  
The comparison of XRPD pattern of the crystals 
obtained from DMF with some major reflection of Form 
II reported by Kato et al. [20] and Cesur and Gokbel [8] 
are illustrated in Fig. 4 (f). The crystallisation of 
mefenamic acid using N, N-dimethyl formamide as a 
solvent produced an XRPD pattern that concurred very 
well with XRPD pattern of Form II reported by those 
literature [8, 20]. This finding demonstrates that 
crystallisation from DMF able to produced mefenamic 
acid crystals Form II. 
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 (f) 
Fig. 4. XRPD pattern of crystals obtained from (a) ethyl acetate; (b) ethanol; (c) IPA, (d) DMA, (e) acetone and (f) DMF in 
comparison with some major reflections with the reference pattern of Form I or Form II obtained from literature.    
Conclusion 
The crystallisation of mefenamic acid using different 
solvents with natural cooling mode produced crystals 
with different polymorphic forms and habits. The results 
of the thermal analysis (DSC), FTIR spectroscopy and 
XRPD have shown that the crystals obtained from EA, 
ethanol, IPA, DMA and acetone are pure Form I, while 
DMF is pure Form II. No solvent entrapment in the 
mefenamic acid crystals were observed during thermal 
studies and the crystals were completely decompose 
during melting. The crystals produced were needle-like 
and cubic shaped crystals, depending on the solvents 
used. 
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